Skip to main content

Table 1 Demographic details of study participants

From: COPD monocytes demonstrate impaired migratory ability

 

COPD (n = 93)

S (n = 29)

HNS (n = 39)

COPD (n = 12) IHC/IF

S (n = 9) IHC/IF

NS (n = 6) IHC/IF

Age

66 (7)

54.4 (7)

41.6 (15.8)

66.3 (4.6)

66.3 (6.6)

70 (5.7)

Gender (F:M)

37:58

14:15

14:25

4:8

4:5

4:2

Current smoker (n)

35

26

0

9

9

0

FEV1% predicted

60.2 (18.9)

98.1 (14.1)

109.6 (14.4)

67.3 (25.6)

91 (11.9)

108 (7.2)

FEV1/FVC (%)

52 (12.5)

75.5 (2.9)

82.5 (6.9)

67.3 (25.6)

91 (11.9)

108 (7.2)

GOLD I (%)

18.3

-

-

33.3

-

-

GOLD II (%)

50.5

-

-

25

-

-

GOLD III (%)

26.9

-

-

41.7

-

-

GOLD IV (%)

4.3

-

-

0

-

-

CAT

17.1 (7.8)

     

SGRQ

39.4 (20.3)

     

Smoking history (Pack Years)a

37 (13-122)

30.5 (12-67)

0

42 (13-126)

50 (21-66)

 

ICS (%)

65

-

-

   
  1. This table shows the grouped demographic details of subjects who participated MSD plasma cytokine analysis, flow cytometric (FACS) & qPCR, chemotaxis (displayed on the left); lung immunohistochemistry/immunofluorescence (displayed on the right). Data is described by mean (SD). aData shown as median (range) Abbreviations: FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, CAT COPD Assessment Test and SGRQ St George’s Respiratory Questionnaire, ICS inhaled corticosteroid, IHC Immunohistochemistry, IF Immunofluorescence, NS non smoker